BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer. Utilizing the same mRNA technology as Covid-19 vaccines, BNT116 aims to prime ...

Medscape Medical News, June 30, 2023 BioNTech, OncoC4 Start Late-Stage Lung Cancer Drug Trial BioNTech and its US partner OncoC4 say they have started a late-stage study of their lung cancer ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Goshen Center for Cancer Care is recognizing the completion of 50 procedures utilizing cutting-edge robotic technology to provide a less invasive option to biopsy lung lesions. The Galaxy System is a ...

29 from 7:30 a.m. until 12 p.m. The event helps the ALA continue the progress in efforts to defeat lung cancer and lung disease. It’s also an occasion to honor the ones who died from lung cancer ...

An analysis of patients with lung metastases from colorectal ... 2024 BioNTech Says FDA Lifts Partial Hold on Its Cancer Drug Trial BioNTech on Monday said the U.S. Food and Drug Administration ...